Amarantus Biosciences Inc. is an early stage biotech devoted to controlling diseases related to programmed cell death. Its lead program focuses on mesencephalic astrocyte-derived neurotrophic factor (MANF) as a therapeutic protein for conditions such as Parkinson's disease and traumatic brain injury.